News
CVRX
8.36
-9.33%
-0.86
Weekly Report: what happened at CVRX last week (0429-0503)?
Weekly Report · 17h ago
The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%
CVRx, Inc. Shares are down a considerable 47% in the last month. The company's price-to-sales ratio of 4.7x is still high compared to the medical equipment industry. CVRx's P/S ratio remains high on the merit of its strong future revenues. Despite the fall in share price, the company has posted impressive revenue growth.
Simply Wall St · 2d ago
CVRx Is Maintained at Buy by Lake Street
Dow Jones · 5d ago
CVRx Price Target Cut to $18.00/Share From $35.00 by Lake Street
Dow Jones · 5d ago
Lake Street Maintains Buy on CVRx, Lowers Price Target to $18
Benzinga · 5d ago
CVRx Is Maintained at Buy by Canaccord Genuity
Dow Jones · 5d ago
CVRx Price Target Cut to $14.00/Share From $32.00 by Canaccord Genuity
Dow Jones · 5d ago
Canaccord Genuity Maintains Buy on CVRx, Lowers Price Target to $14
Benzinga · 5d ago
Dow Jumps 200 Points Following Fed Decision; Pfizer Earnings Top Estimates
The Dow Jones index gained over 200 points on Wednesday. The Federal Reserve opted to keep the federal funds rate unchanged at 5.25% to 5.5%. Pfizer reported better-than-expected first-quarter financial results. In commodity news, oil traded down 3.3% to $79.23 while gold traded up.
Benzinga · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Viking Holdings, ETSY, PPL Corp
U.S. Stocks are set to open lower on Wednesday. The Dow Jones Industrial Average was up 0.40% and the S&P 500 was down 0.20%. Chip stocks led losses after downbeat results. The Federal Reserve's interest rate decision is scheduled for later in the day.
Reuters · 5d ago
CVRx Coverage Assumed by Craig-Hallum at Buy
Dow Jones · 5d ago
CVRx Price Target Cut to $23.00/Share From $30.00 by Craig-Hallum
Dow Jones · 5d ago
Craig-Hallum Assumes CVRx at Buy, Lowers Price Target of $23
Benzinga · 5d ago
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Advanced Micro Devices, Inc. Shares dipped 6.9% to $147.44 on Wednesday. The company reported first-quarter results and issued revenue guidance for the second quarter. Shares of cannabis-related stocks traded higher following reports suggesting DEA plans to reclassify cannabis as a less dangerous drug.
Benzinga · 5d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
CytomX Therapeutics stock increased by 154.6% to $4.15 during Wednesday's regular session. Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 36.79%. CVRx and Mobile-health Network among the losers.
Benzinga · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Powell Industries, Bio-Techne, ADP
The tech-heavy Nasdaq and the benchmark S&P 500 slipped on Wednesday. The Dow Jones Industrial Average was up 0.28% and the Nasdaq Composite was down 0.33%. Chip stocks led losses on downbeat results and fresh economic data ahead of the Federal Reserve's interest rate decision.
Reuters · 5d ago
CVRx stock plunges 42% in wake of Q1 report, updated forecast
CVRx stock plunges 42% in wake of Q1 report, updated forecast. The medical device maker released a disappointing Q1 earnings report and issued guidance that fell short of Street expectations. CVRx now expecting Q2 revenue of $11.3M to $12.3m and 2024 revenues of $50m to $53m.
Seeking Alpha · 5d ago
CRVx stock plunges 42% in wake of Q1 report, updated forecast
Medical device maker CRVx stock plunges 42% in wake of Q1 report, updated forecast. CVRx now expecting Q2 revenue of $11.3M to $12.3m, down from Q1's $10.8M. The company's Q1 revenue rose 35% year-over-year.
Seeking Alpha · 5d ago
Piper Sandler Remains a Buy on CVRx (CVRX)
TipRanks · 5d ago
CVRx Cut to Market Perform From Outperform by William Blair
Dow Jones · 5d ago
More
Webull provides a variety of real-time CVRX stock news. You can receive the latest news about Cvrx, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CVRX
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.